+34 620 10 75 37info@nanbiosis.com

Posts on Jan 1970

New Solutions to Old challenges: Key Symposium on Nanomedicine Against Cancer

Symposium on nanomedicine vs cancer: experts gather Nov 28 in Málaga to tackle tumor-targeting challenges and advance innovative therapies.

Málaga, november 2024. On November 28th at 9:00 AM, the Salón de Actos at IBIMA (C/Severo Ochoa, 35, Málaga) will host the symposium “Targeting in Nanomedicine Against Cancer,” bringing together leading experts to discuss the critical challenges and advances in applying nanomedicine to oncology. Organized by IBIMA, this event will shed light on one of the most pressing issues in cancer nanomedicine: the difficulty of delivering nanostructures to tumor cells.

The challenges to overcome cancer

Cancer remains one of the world’s most significant health challenges, with nearly 20 million new cases annually and 9.7 million deaths in 2022. Despite notable advances in treatments—ranging from surgery and radiotherapy to immunotherapy and metabolic therapies—many patients continue to face poor outcomes. Nanomedicine has generated substantial excitement over the last three decades, particularly since the approval of Doxil™, the first nanomedicine for cancer. However, challenges persist.

Structure of Doxil. Source: media.springernature.com

One critical barrier is the targeting of nanostructures. Current technologies allow less than 1% of nanoparticles to reach tumor sites, with only a fraction successfully interacting with tumor cells. Addressing this bottleneck is essential for unlocking the full potential of nanomedicine in cancer treatment.

Featured Talks by NANBIOSIS Researchers

Several distinguished researchers from NANBIOSIS Units will present their work during the symposium. They will offer insights into cutting-edge strategies to overcome the targeting challenge:

  • Dr. Jesús Santamaría (NANBIOSIS Unit 9, Universidad de Zaragoza): “Nanomedicine. Achievements and Limitations: The Targeting Problem with Nanoparticles in Cancer and Their Limited Clinical Translation”.
  • Dr. Ana Martín Pardillos (NANBIOSIS Unit 9, Universidad de Zaragoza): “Targeting Strategies Based on Cells as Nanoparticle Vectors”.
  • Dr. Ibane Abasolo (NANBIOSIS Unit 20, Vall d’Hebron Research Institute, Barcelona): “Targeting Strategies Based on Extracellular Vesicles as Nanoparticle Vectors”.
  • Dr. Carlos Caro (NANBIOSIS Unit 28, IBIMA Plataforma BIONAND, Málaga): “In Vivo Nanoparticle Tracking: Biodistribution and Non-Invasive Techniques”.
  • Dr. María Luisa García-Martín (NANBIOSIS Unit 28, IBIMA Plataforma BIONAND, Málaga): “Biological Barriers and Tumor Targeting“.

Bridging Science and Clinical Application

This symposium offers a unique platform for dialogue among researchers, clinicians, and industry professionals, fostering collaborations to advance the practical application of nanomedicine in cancer treatment. With its focus on innovative targeting solutions, the event promises to contribute significantly to overcoming one of the most challenging hurdles in oncology.

Mark your calendar and join us at IBIMA on November 28th to explore the future of nanomedicine in cancer treatment.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Read More

Jesús Santamaría awarded with the ‘Aragón Investiga’ for his Research Excellence

Prof. Jesús Santamaría, Director of NANBIOSIS Unit 9, wins the Aragón Investiga Award for his pioneering contributions to nanomaterials and research excellence.

Zaragoza, november 2024. The Aragón Investiga Award for Research Excellence has been awarded to Prof. Jesús Santamaría Ramiro, a distinguished researcher and Full Professor of Chemical Engineering at the University of Zaragoza, and Scientific Director of Unit 9 of NANBIOSIS.

Prof. Santamaría is the principal investigator of the Nanostructured Films and Particles group, where Unit 9 is located. He is also a key member of the Institute of Nanoscience and Materials of Aragón (INMA), a Severo Ochoa Center of Excellence jointly supported by the University of Zaragoza and CSIC.

A brilliant scientific career

Recognized as one of Europe’s leading researchers in the synthesis and applications of nanomaterials, Prof. Santamaría has dedicated his career to pioneering advanced methods for nanomaterial synthesis using non-conventional technologies. His work has found groundbreaking applications in nanomaterials, unconventional catalysis, and molecular recognition, significantly advancing these fields.

Among his most notable achievements are the foundation of the Aragón Institute of Nanoscience and the receipt of two prestigious Advanced Grants from the European Research Council (ERC), a testament to the transformative impact of his work.

The award was presented by Claudia Pérez Forniés, Regional Minister of Education, Science and Universities, of Aragón, during a ceremony that celebrated excellence in research and innovation.

NANBIOSIS congratulates Prof. Jesús Santamaría on this well-deserved recognition and celebrates his enduring contributions to the advancement of nanoscience and its applications.

Prof. Santamaría serves as the Scientific Director of the NANBIOSIS Unit 9 (Synthesis of Nanoparticles Unit), a facility dedicated to the development of nanoparticles and nanostructures for biomedical and technological applications. The Unit plays a crucial role in supporting cutting-edge research through its state-of-the-art synthesis capabilities.

Frame capture of Prof. Santamaría, Scientific Director of Unit 9, during an interview at a local TV channel.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Read More

NANBIOSIS in the CIBER Conference in Valencia

NANBIOSIS will showcase its services and present the Chips R’ Us project at the 10th Anniversary CIBER Conference in Valencia, Nov 27-30, 2024.

Valencia, november 2024. In cellebration of the 10th anniversary of the CIBER network, CIBER is organizing a special edition of its Scientific Conference 2024, which will take place in Valencia on November 27-30, 2024. This prestigious event, which is expected to gather over 1500 researchers, clinicians, and key stakeholders in biomedical innovation, serves as a vital platform for presenting cutting-edge scientific achievements and fostering collaborations within the Spanish research ecosystem.

This year, NANBIOSIS will have a significant presence at the conference. We will activelly participate in the organization of the event, demonstrating our continued commitment to advancing biomedical research through innovation and collaboration.

NANBIOSIS at the Conference

During the conference, NANBIOSIS will showcase its services and capabilities at a dedicated stand, shared with other leading scientific platforms. This joint exhibition aims to highlight the synergies and resources available within the Spanish scientific community, promoting the integration of multidisciplinary approaches to address complex biomedical challenges.

In addition to its presence at the stand, NANBIOSIS will also take center stage during the closing session of the conference, where Chips R’ Us, a pioneering project coordinated by the platform, will be presented. This project, in which four different CIBER platforms participate (CIBER-BBN, CIBERES, CIBER-INFEC and CIBER-ONC), exemplifies the innovative research fostered by NANBIOSIS and its impact on translational medicine.

The CHIPS R’ US project aims to improve the study and treatment of Lower Respiratory Tract Infections (LRTI), a leading cause of child mortality. The project aims to replicate a realistic lung microenvironment using Organ-on-chip technology. This approach allows precise emulation of respiratory conditions and enables real-time monitoring with advanced imaging tools. Coordinated by NANBIOSIS, the project fosters collaboration across four CIBER areas (BBN, ES, INFEC, ONC) and lays the groundwork for future interdisciplinary initiatives.

Solidarity and Commitment: CIBER Stands with Valencia

As stated by the organization of the event: “We express our solidarity with Valencia and its residents following the effects of the DANA and confirm that the congress will proceed as planned, reaffirming our commitment to scientific development”. The webpage of the conference also stated that “We firmly believe that moving forward with the CIBER Congress is our best way to support the Valencian Community while maintaining our commitment to the scientific community and society at large.”

A Key Venue for Biomedical Innovation

The conference program includes a mix of plenary sessions, round tables, poster presentations, and networking activitis, covering diverse areas such as personalized medicine, advanced therapies, and health technology. By bringing together experts from various disciplines, the event creates opportunities for the exchange of ideas and the development of groundbreaking solutions to improve patient care.

NANBIOSIS invites all attendees to visit its stand to learn more about its state-of-the-art services and to attend the closing session to discover the outcomes of Chips R’ Us. As a key participant in this 10th Anniversary CIBER Scientific Conference, NANBIOSIS reaffirms its position as a leader in enabling high-impact biomedical research.

For more information about the event, please visit the CIBER Annual Scientific Conference website.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Read More

The Protein Production Platform (PPP) at the UAB Innovation Fair

The PPP advances antimicrobial peptide research, forging partnerships to combat antibiotic resistance and prevent medical device-related infections.

Barcelona, october 2024. During Antibiotic Awareness Week, we spotlight the Protein Production Platform (PPP) at NANBIOSIS Unit 1 for its pivotal role in combating antimicrobial resistance.

At the recent UAB Innovation Fair, the PPP showcased its cutting-edge technologies and established collaborations with experts in bacterial biofilms and nanomaterials. Together, they aim to develop innovative antimicrobial peptides as alternatives to traditional antibiotics, targeting nosocomial infections linked to medical devices. These efforts underscore the critical importance of advancing research and partnerships to address one of the greatest global health challenges: antibiotic resistance.

Protein Production Platform at the UAB Innovation Fair

Las month, our Unit 1, also known as Protein Production Platform (PPP), participated in the second edition of the UAB Innovation Fair, held at the Autonomous University of Barcelona (UAB). The event served as a vibrant meeting point for research groups, spin-offs, and companies, all focused to explore potential synergies and collaborative opportunities.

The fair provided an excellent platform for the PPP to showcase its capabilities and services. During the event, our Unit established valuable contacts with several diagnostic companies and protein research groups. These interactions not only highlighted the potential benefits these entities could gain from our services, but also opened the door to collaborations that could further enhance the platform’s offerings.

In addition to these interactions, the PPP, as part of the Nanobiotechnology (NBT) research group, connected with specialists in bacterial biofilms and nanomaterials. These experts expressed interest in collaborating on our research focused on antimicrobial peptides aimed at developing alternatives to traditional antibiotics, with the goal of preventing nosocomial infections associated with medical devices.

The PPP’s active participation in the UAB Innovation Fair not only highlights its commitment to advancing scientific research but also demonstrates its dedication to creating impactful partnerships. By engaging with a diverse array of stakeholders, the PPP is well-positioned to drive forward innovative solutions and contribute to the broader scientific community.

The fair was a resounding success, providing a dynamic environment for knowledge exchange and collaboration. The PPP looks forward to building on the connections made during the event and continuing to play a crucial role in the advancement of protein production technologies, nanobiotechnology research, as well as the ongoing battle against antimicrobial resistance.

The Protein Production Platform (PPP), also known as NANBIOSIS Unit 1, specializes in the production, purification, and characterization of recombinant proteins and biomaterials. It leverages state-of-the-art technologies to support biomedical and nanotechnology research, focusing on applications such as cancer treatment, antimicrobial resistance, and advanced protein delivery systems. Operated by the Nanobiotechnology Group at the Autonomous University of Barcelona, it serves academic and industrial clients with customized solutions for protein engineering and synthesis.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Read More

European Partnership Opens a New Era in Rare Disease Research

The European Rare Diseases Research Alliance (ERDERA) kicked off last month, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.

Paris, october 2024. The European Rare Diseases Research Alliance (ERDERA), a new initiative under Horizon Europe, has officially launched with an ambitious mission to improve the lives of 30 million people affected by rare diseases across Europe and beyond.

Backed by a budget of €380 million, ERDERA brings together more than 170 organizations from the public and private sectors, led by the National Institute of Health and Medical Research (INSERM) in France. This collaborative effort aims to advance research on prevention, diagnosis, and treatment for rare diseases, creating a robust infrastructure for innovation and patient support.

ERDERA’s focus is to build on the successes of previous projects, such as the European Joint Programme on Rare Diseases (EJP RD) and the SOLVE-RD project. It strives to create a seamless network of resources and expertise, fostering a globally competitive European research area for rare diseases.

NANBIOSIS participation in ERDERA

CIBER-BBN group led by Ramón Martínez, director of NANBIOSIS and Scientific Director of our Unit 26, together with Juan Antonio Bueren’s group (CIBERER), will participate in a work package aimed at accelerating key technologies in the field of advanced therapies. Specifically, these two CIBER areas will develop new gene and gene-editing therapies, both viral and non-viral, for rare diseases affecting hematopoietic, epidermal, inflammatory, and metabolic disorders. They will employ in vitro and in vivo approaches, as well as lipid nanoparticles for the encapsulation and controlled release of mRNA.

Unit 26 specializes in Nuclear Magnetic Resonance (NMR) technology, providing valuable capabilities for acquiring unique metabolic profiles from a variety of biological samples, including biofluids, cell lines, tissues, and animal models such as mice and rats.

This expertise is crucial in uncovering molecular markers that can help researchers better understand rare diseases, ultimately contributing to the development of more precise diagnostic and therapeutic strategies.

NANBIOSIS Unit 26’s NMR capabilities complement ERDERA’s clinical research network, which aims to accelerate diagnostics and increase clinical trial readiness for rare diseases. The alliance’s comprehensive support services, including a Data Services Hub and an Expertise Services Hub, will benefit from the detailed metabolic profiling provided by Unit 26, further strengthening the infrastructure available to researchers.

Daria Julkowska, ERDERA’s scientific coordinator, highlighted the alliance’s vision of integrating cross-disciplinary expertise under a unified mission: “We have a tripartite mission: One; to bring under one roof a broad range of high-value services, resources and cross-disciplinary expertise to support rare disease research; Two, to boost clinical research by enabling every consenting patient living with a rare disease to be findable and enrolled in a suitable clinical study and finally, to spur innovation and EU competitiveness, through investment but also by aligning regional, national and European research strategies, and fostering collaboration among all stakeholders at a global scale.”

ERDERA’s roadmap, presented during its launch event on 28 October 2024, underscores the importance of collaborations with specialized research infrastructures like NANBIOSIS. Together, these efforts aim to bridge gaps in diagnosis and treatment for rare diseases, transforming the landscape of patient care in Europe.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Read More